Amarantus Bioscience Holdings Inc (AMBS)

[EDHustle]

AMBS is on PSP Radar


PSP Members,

After our huge win last week, I found an AWESOME new pick to kick-start August and get us off to a great start.

Our new pick is a biotech play that is currently working with the world-famous Michael J. Fox Foundation on a treatment for Parkinson's disease!

The company is brand new to trading, and just recently announced positive pre-clinical trials on their treatment called MANF (a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis.)

MANF is a highly potent neurotrophic factor to treat both Parkinson's and Ischemic Heart Disease.

From a technical perspective our new pick looks like a perfect technical play as the stock has leveled off of a double-digit decline last week on rather thin volume.

I believe we're going to see a momentum breakout similar to what we saw on last weeks pick that will make this a perfect bounce play for us next week. The stock is trading at only .30 cents, and is a newly listed company (trading less than 60 days).

Let's be ready for Monday morning's trading session, as our new pick is not only a ground floor opportunity, but also appears positioned for an upward reversal and ready to show us some profits!

-James

++++++++++++++++++++++++++++++++++++++++++++++++++++++++

NEW PICK

Amarantus BioSciences, Inc.
AMBS
AMBS Chart
Currently Trading: $0.30
Real Time 'Bid & Ask' Prices


PSP Members,

After our huge 76% Gainer last week, I went looking for another potential winner that would get August off to a rocking start. I've discovered a biotech play with breakthrough results in clinical trials that could spark the beginning of the end of Parkinson's disease and other ailments. Not only does this company have an outstanding mission, they are also working with the world-renowned Fox Foundation!

AMBS is in the biotechnology sector and is currently developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis.

Please begin your own research immediately for Monday trading!

The stock appears to be a great technical play right now, as investors look to capture profits off of a bounce or reversal in the stock price, having dropped double digits on Friday on rather thin volume.

The growing consensus is that a better price point will spell better profits, especially considering it doesn't take much to move the needle with AMBS. All we need is some momentum and Iexpect that we will likely see strong momentum on AMBS early next week!


About Amarantus:
AMBS is engaged in the research and development of first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases.

Corporate Website: http://www.amarantus.com/


AMBS Breaking News:
Amarantus reports positive data in Parkinson's Program:

AMBS recently announced positive results from a pre-clinical experiment demonstrating that MANF significantly reduces the deficits that cause Parkinson's disease. These experiments were funded by a research grant from the Michael J. Fox foundation. The data demonstrates that MANF is a powerful neuroprotectant that prevents the loss of neuronal viability and function from injury in cellular and rodent models of Parkinson's disease. (read more)


AMBS Other News:
On June 3, 2011, AMBS disclosed entering into a Letter Agreement (the "Agreement") with Generex Biotechnology Corporation ("Generex") regarding the licensing of certain intellectual properties to treat pre-diabetes and forming collaborative arrangements for the benefit of the parties. The Company fully intends to arrive at a consensus with Generex and close the transaction in the near future. (read more)


AMBS Research:
The Company is making great strides in the medical community as they focus their CNS efforts on the advancement of the MANF product development program. MANF is highly indicated for the treatment of several poorly served medical conditions, including Parkinson's disease and Ischemic Heart Disease.

AMBS is executing the protocols required to gain Investigational New Drug status with the FDA.


AMBS Management Spotlight:
Martin D. Cleary - Chairman & Chief Executive Officer
Mr. Cleary is a Columbia University grad and has a career that spans more than 3 decades. He has held several senior management positions with Johnson and Johnson and has raised over $400 million in equity and partnership funds since 1986. Mr Clearly has also either served on the Board, achieved executive status, or founded a number of biotech companies over the years including GenVec, Cytogen Corporation, Theragen, CardioGene Therapeutics, Genteric, Inc., Juvaris BIoTherapeutics, Mela Sciences, Inc., Fish Nature, Inc., and of course Amarantus BioSciences.


AMBS Technical Specs:

AMBS is a newly listed stock (it has only traded since mid-June) with momentum only picking up the past couple of weeks, as AMBS traded down from it's recent high on June 15 to its current price around 30 cents, and now has hit bargain-basement levels, and appears too good to pass up.

The RSI closed Friday around 33 points, so we're right at a turnaround point. Anything near or fewer than 30 is considered bullish, since the stock is oversold and is measured to rise from here. The interest in AMBS seems to gaining momentum indeed.

I believe AMBS is set for an upward trend reversal after a sell off on Friday. I also link a jump in the average volume, from 80,000 shares over the past 5 days, compared to only 34,000 shares over the past 30 days, to a growing demand that could spell potential profits for members. It doesn't take much to move the needle as AMBS is a thinly traded stock right now, so a buildup of momentum should send AMBS up-and-to-the-right rather quickly!

Add AMBS to your stock watch immediately!

Amarantus has a life mission that dispels the notion that they are a typical penny stock Company without any long-term intentions. When a Company is involved in the treatment of human disease with an experienced CEO at the level that AMBS does the investment community tends to pay attention.

Keep your eyes on that big bounce that I expect will come Monday. Now let's go and make some money!

As always please do your own research this weekend, and keep a close eye on AMBS.OB Monday especially, as I think the markets will make a push with the debt plan needing a vote by Tuesday.

Happy Trading

-James




















Disclaimer: (Please Read)

Never invest in any stock featured on the PennyStockProphet.com website or email alerts unless you can afford to lose your entire investment. Many of the stocks featured are highly speculative. PennyStockProphet.com expects to be compensated up to Fifty Thousand Dollars by a third party for a one week advertising agreement regarding Amarantus BioSciences Inc (AMBS.OB) The third party may have shares and may sell their shares at any time. Please understand that it is possible that this could have a negative affect on the share price. Neither James Connelly nor PennyStockProphet.com employees are registered as investment advisors, financial analysts, brokers, or dealers in any jurisdiction whatsoever. Your use of the PennyStockProphet.com website, email alerts, and all other services means that you agree to hold PennyStockProphet.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation for the purchase or sale of any securities. The information provided is obtained from sources deemed reliable, but PennyStockProphet.com does not guarantee in any way the timeliness, sequence, accuracy, adequacy, or completeness of such information made regarding stocks discussed on PennyStockProphet.com or in email alerts. The owner, publisher, editor and their associates are not responsible for errors and omissions. You understand and agree that at the time of any transaction you make James Connelly, PennyStockProphet.com employees, PennyStockProphet.com affiliates, and friends and family of James Connelly may have a position in such securities. The position may have been acquired prior to the publication of any website information or email alert. You should also be aware that the aforementioned parties do have the right to sell their positions at any time without further notification. Any opinions expressed are subject to change without notice. PennyStockProphet.com encourages readers and investors to supplement the
information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or persons affiliated with or associated with such companies; or is available from public sources. Read our full disclaimer at:

http://pennystockprophet.com/Disclaimer.html